Insider Buying: Vivani Medical, Inc. (NASDAQ:VANI) Director Buys 44,400 Shares of Stock

Vivani Medical, Inc. (NASDAQ:VANI - Get Free Report) Director Gregg Williams acquired 44,400 shares of Vivani Medical stock in a transaction on Monday, April 7th. The shares were purchased at an average price of $0.99 per share, for a total transaction of $43,956.00. Following the completion of the purchase, the director now directly owns 4,799,200 shares of the company's stock, valued at approximately $4,751,208. This represents a 0.93 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Gregg Williams also recently made the following trade(s):

• On Friday, April 11th, Gregg Williams acquired 2,311 shares of Vivani Medical stock. The shares were purchased at an average price of $1.01 per share, with a total value of $2,334.11.
• On Wednesday, April 9th, Gregg Williams bought 18,529 shares of Vivani Medical stock. The stock was acquired at an average cost of $1.02 per share, for a total transaction of $18,899.58.
• On Friday, April 4th, Gregg Williams purchased 34,000 shares of Vivani Medical stock. The shares were acquired at an average cost of $0.99 per share, with a total value of $33,660.00.
• On Wednesday, April 2nd, Gregg Williams acquired 2,000 shares of Vivani Medical stock. The stock was acquired at an average cost of $1.01 per share, for a total transaction of $2,020.00.

Vivani Medical Stock Up 1.0 %

Shares of NASDAQ VANI traded up $0.01 during midday trading on Friday, reaching $1.02. 54,177 shares of the company were exchanged, compared to its average volume of 170,112. The stock's 50-day moving average price is $1.09 and its 200-day moving average price is $1.19. The stock has a market cap of $60.42 million, a P/E ratio of -2.27 and a beta of 2.76. Vivani Medical, Inc. has a one year low of $0.91 and a one year high of $2.09.

Vivani Medical (NASDAQ:VANI - Get Free Report) last issued its quarterly earnings data on Monday, March 31st. The company reported ($0.11) earnings per share for the quarter, missing analysts' consensus estimates of ($0.10) by ($0.01). On average, equities research analysts anticipate that Vivani Medical, Inc. will post -0.41 EPS for the current year.

Analyst Ratings Changes

Separately, HC Wainwright reissued a "buy" rating and issued a $4.00 target price on shares of Vivani Medical in a report on Friday, April 4th.

Institutional Investors Weigh In On Vivani Medical

Hedge funds have recently added to or reduced their stakes in the business. Wealthedge Investment Advisors LLC acquired a new position in shares of Vivani Medical during the fourth quarter worth $43,000. Jane Street Group LLC bought a new stake in shares of Vivani Medical in the 4th quarter valued at about $66,000. Northern Trust Corp increased its stake in shares of Vivani Medical by 19.1% in the fourth quarter. Northern Trust Corp now owns 71,915 shares of the company's stock valued at $83,000 after buying an additional 11,540 shares during the period. Finally, Geode Capital Management LLC raised its position in shares of Vivani Medical by 4.6% during the third quarter. Geode Capital Management LLC now owns 342,891 shares of the company's stock worth $401,000 after acquiring an additional 15,008 shares during the last quarter. 6.78% of the stock is currently owned by institutional investors and hedge funds.

About Vivani Medical

Vivani Medical, Inc, a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals.